Ventyx Biosciences Inc (VTYX)
2.18
-0.04
(-1.80%)
USD |
NASDAQ |
Jul 05, 16:00
2.175
0.00 (0.00%)
After-Hours: 20:00
Ventyx Biosciences Research and Development Expense (TTM): 174.08M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 174.08M |
| December 31, 2023 | 175.77M |
| September 30, 2023 | 163.93M |
| June 30, 2023 | 139.65M |
| March 31, 2023 | 105.77M |
| December 31, 2022 | 87.74M |
| Date | Value |
|---|---|
| September 30, 2022 | 71.38M |
| June 30, 2022 | 56.45M |
| March 31, 2022 | 51.29M |
| December 31, 2021 | 58.48M |
| September 30, 2021 | 45.96M |
| June 30, 2021 | 37.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
37.41M
Minimum
Jun 2021
175.77M
Maximum
Dec 2023
97.33M
Average
79.56M
Median
Research and Development Expense (TTM) Benchmarks
| Anavex Life Sciences Corp | 38.28M |
| Checkpoint Therapeutics Inc | 36.24M |
| CEL-SCI Corp | 19.98M |
| AIM ImmunoTech Inc | 10.84M |
| IGC Pharma Inc | 3.773M |